Welcome to Debate Club! Please be aware that this is a space for respectful debate, and that your ideas will be challenged here. Please remember to critique the argument, not the author.

The GLP-1 juggernaut is slowing. Eli Lily missed a sales target.

Options
MargaretYakoda
MargaretYakoda Posts: 2,995 Member
edited April 27 in Debate Club
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-misses-third-quarter-profit-amid-soaring-demand-weight-loss-drug-2024-10-30/

Looks like there’s a limit to demand for GLP-1 meds.

Replies

  • SafariGalNYC
    SafariGalNYC Posts: 2,259 Member
    @MargaretYakoda interesting.

    Some off the cuff thoughts-

    At some point it has to be an oversaturated market.
    When we get to the point.. I don’t know.

    According to an article in cnbc today, Eli reps said it’s was a problem with “inventory stocking .”

    “The primary culprit was an inventory hit to Mounjaro and Zepbound ... not weaker demand," Citi analyst Geoff Meacham wrote in a research note Wednesday.

    Jared Holz, Mizuho health-care equity strategist, wrote in an email that "destocking" — or selling existing inventory for the drugs rather than stocking up on more — came as a surprise, especially with the high level of demand for the treatments.”


    =>Eli Lilly has invested $15 billion to expand manufacturing capacity for its injectable drugs for 24-25. Im sure we will be inundated with advertisements with happy skinny people.

    How much of the injectable - medicalized weight loss use is just great marketing?

  • chris_in_cal
    chris_in_cal Posts: 2,825 Member
    Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling

    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-misses-third-quarter-profit-amid-soaring-demand-weight-loss-drug-2024-10-30/

    Looks like there’s a limit to demand for GLP-1 meds.

    It was just FDA approved for sleep apnea and next is Medicare adding it to approved treatments. That can't hurt the company's sales.
  • sollyn23l2
    sollyn23l2 Posts: 2,036 Member
    Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling

    https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-misses-third-quarter-profit-amid-soaring-demand-weight-loss-drug-2024-10-30/

    Looks like there’s a limit to demand for GLP-1 meds.

    It was just FDA approved for sleep apnea and next is Medicare adding it to approved treatments. That can't hurt the company's sales.

    My understanding is that Medicare won't approve it because it would bankrupt them to pay out that much for a single medication for so many people🤷‍♀️ but I don't know
  • chris_in_cal
    chris_in_cal Posts: 2,825 Member
    Looks like there’s a limit to demand for GLP-1 meds.

    It sounds like it's a made up limit. Between sleep apnea, obesity, and diabetes I'm sure some clients are still interested in getting treated.
    sollyn23l2 wrote: »
    Medicare won't approve it because it would bankrupt them to pay out that much for a single medication for so many people

    Yeah, it such a good idea to have these meds prices negotiated by the Feds. Like every other country in the world. Lily gets their dough, and patients get top care.
  • SafariGalNYC
    SafariGalNYC Posts: 2,259 Member
    edited December 2024
    Theoldguy1 wrote: »
    Looks like there’s a limit to demand for GLP-1 meds.

    It sounds like it's a made up limit. Between sleep apnea, obesity, and diabetes I'm sure some clients are still interested in getting treated.
    sollyn23l2 wrote: »
    Medicare won't approve it because it would bankrupt them to pay out that much for a single medication for so many people

    Yeah, it such a good idea to have these meds prices negotiated by the Feds. Like every other country in the world. Lily gets their dough, and patients get top care.

    In many European countries these drugs are self pay.

    https://www.euronews.com/health/2024/10/11/france-wont-pay-for-weight-loss-drug-wegovy-what-about-other-european-countries#:~:text=Wegovy is expected to cost,to help patients shed weight.

    Besides France, Germans pay out of pocket if they want to use this drug. Germany considers obesity a “lifestyle choice.”

    - a 1980s law bans Germany's national health system from paying for drugs that target “lifestyle” issues like obesity, smoking cessation, hair growth, and erectile dysfunction.

  • changewewanttosee
    changewewanttosee Posts: 239 Member
    is this a debate on the ethical use of these meds for non health related reasons..... or the un ethical use of advertising in pushing these meds? Because I am not impressed by these drug companies one bit.